What is the maximum recommended dose of Effexor (venlafaxine) per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Dose of Effexor (Venlafaxine)

The maximum recommended dose of Effexor (venlafaxine) is 375 mg/day, administered in divided doses (typically three times daily for immediate-release formulation). 1

Standard Dosing Framework

  • Starting dose: 75 mg/day in two or three divided doses with food 1
  • Typical therapeutic range: 150-225 mg/day for most indications 1
  • Maximum approved dose: 375 mg/day 1

When Higher Doses Are Considered

More severely depressed inpatients may benefit from doses approaching the maximum, as they have been shown to respond to mean doses of 350 mg/day 1. The FDA label explicitly states that certain patients, including more severely depressed individuals, may respond better to higher doses up to the 375 mg/day maximum 1.

Clinical Contexts for High-Dose Use

High-dose venlafaxine (≥375 mg/day) is increasingly considered in clinical practice for:

  • Treatment-resistant depression 2
  • Obsessive-compulsive disorder 2
  • Patients with known CYP2D6/CYP2C19 poor metabolizer phenotype in their family history 2
  • Patients taking multiple concurrent medications 2

Dose Titration Requirements

  • Increments: Up to 75 mg/day 1
  • Minimum interval between increases: 4 days 1
  • Time to reach efficacious dose for pain: Typically 2-4 weeks 2

Critical Safety Monitoring at Higher Doses

Blood Pressure Monitoring

Blood pressure monitoring is essential, particularly when exceeding 150 mg/day, as venlafaxine causes dose-dependent increases in blood pressure 3. This is one of the most important safety considerations distinguishing venlafaxine from SSRIs 2, 4.

Cardiac Considerations

  • Cardiac conduction abnormalities have been reported in a small number of patients, requiring caution in those with cardiac disease 2
  • Unlike tricyclic antidepressants, venlafaxine does not significantly affect cardiac conduction in most patients 4

Dose Reductions for Special Populations

Hepatic Impairment

  • Reduce total daily dose by 50% in patients with mild to moderate hepatic impairment 1
  • May require even greater reduction due to individual variability in clearance 1

Renal Impairment

  • Reduce total daily dose by 25% for mild to moderate renal impairment (GFR 10-70 mL/min) 1
  • Reduce total daily dose by 50% for patients undergoing hemodialysis 1

Elderly Patients

  • No specific dose adjustment recommended based on age alone 1
  • Exercise caution and take extra care when increasing doses 1

Discontinuation Protocol

Taper venlafaxine over 10-14 days when discontinuing to prevent withdrawal syndrome 2, 3. Abrupt discontinuation should be avoided as withdrawal symptoms are well-documented 2.

Pharmacogenetic Considerations

For CYP2D6 poor metabolizers, consider switching to an alternatively metabolized antidepressant rather than dose reduction, as these patients have significantly reduced clearance and higher risk for adverse effects 2. This is preferred over attempting to carefully monitor lowered doses 2.

Common Pitfalls to Avoid

  • Do not exceed 225 mg/day in outpatient settings for moderately depressed patients, as there is no evidence of additional benefit 1
  • Do not increase doses more frequently than every 4 days to allow adequate assessment of tolerability 1
  • Do not neglect blood pressure monitoring, especially above 150 mg/day 3
  • Do not abruptly discontinue without tapering 2, 3

Tolerability at High Doses

Clinical evidence demonstrates that venlafaxine can be tolerated at doses up to 600 mg/day in some patients, though increased frequency and severity of side effects occur at higher doses 5. The most common adverse events include headache, insomnia, nausea, constipation, diaphoresis, and dry mouth 6.

References

Guideline

Dose-Response Relationship and Safety Considerations for Venlafaxine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Venlafaxine Dosing and Safety Considerations for Anxiety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Tolerability of high-dose venlafaxine in depressed patients.

Journal of psychopharmacology (Oxford, England), 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.